Adalimumab Product Approval Information - Licensing Action 12/31/02

Proper name: Adalimumab
Tradename: HUMIRA
Manufacturer: Abbott Laboratories, Abbott Park, IL, License #0043
Indication for Use: For reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be used alone or in combination with Methotrexate (MTX) or other DMARDs.
Approval Date: 12/31/2002
Type of submission: Biologics license application


Label (PDF)

Clinical Review - Part 5 (PDFs)

Chemistry Review (PDF)

Clinical Pharmacology and Biopharmaceutics Review (PDF)

Pharmacology Review (PDF)

Statistical Review (PDF)

Page Last Updated: 04/01/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English